Dow hits record highs as Tesla and Lilly crush it — rotate into old-economy winners

Verdict: skip the trade — the rotation thesis is real but the strategy and TSLA fundamentals don't support it

The rotation narrative is real — the CNBC coverage confirms the Dow hitting records while the Nasdaq slipped, and Eli Lilly's 44.7% revenue growth with a 77.8% return on equity is the kind of fundamental backing a thesis needs. But this strategy trades TSLA, not the rotation theme, and Tesla's own numbers undercut the bull case: revenue contracted 2.9%, diluted EPS fell 47.1%, and the gross margin sits in just the 21st percentile of its sector. The backtest seals the verdict — while the 60-month window showed a 6.9% return, the most recent 24-month window lost 7.5% with a 33% win rate, and every parameter variant failed the final 12-month holdout, producing a no-recommendation result. No robust setup was established, and with TSLA trading at $380.84 against a 50-day SMA of $400.59 and an ADX of 14.4 versus the required 25, the entry conditions are not close to triggering today. Wait for a fundamental catalyst that actually reverses Tesla's margin and earnings trajectory before deploying capital. **Conviction breakdown:** - **Thesis support (58):** The old-economy rotation is genuine and well-documented, but Tesla's contribution to the thesis is the weakest link. - **Trade readiness (30):** TSLA is below its 50-day SMA and ADX is far below the entry threshold; the setup is not near firing. - **Risk quality (45):** A 12% stop on a stock with 42.9% annualized volatility and a 53.8% historical drawdown leaves meaningful gap risk unaddressed. - **Backtest evidence (35):** The holdout returned -7.6% with a 26.4% win rate, and no parameter variant was recommended. - **Fundamentals trend (50):** Eli Lilly's numbers are elite, but TSLA's revenue contraction and margin percentile drag the basket's fundamental quality down.

Trade now: TSLA entry blocked by trend strength

**Current state: wait.** TSLA closed the latest session at $380.84. The first entry condition — price above $3.00 — is trivially met. The trend condition is not: price sits $19.75 below the 50-day simple moving average at $400.59, leaving it close but unmet. The real blockers are ADX (14) and OBV. TSLA's ADX (14) sits at 14.4, and the strategy requires it above 25 to confirm a trending move, so it needs to climb roughly 11 points from here. That gap puts the condition status at "far," meaning no meaningful trend strength is present today. OBV is reporting as unknown, which means the volume-confirmation gate cannot be evaluated until a live feed supplies a value. On the risk side, the strategy's fixed stop loss is 12% and the primary take-profit target is 20%, giving an effective reward-to-risk ratio of roughly 1.67:1 at the rule level. In price terms on TSLA, a hypothetical entry at $380.84 would place the stop near $335.14 and the first profit target near $457.01. "Wait" means do nothing until ADX pushes through 25 and OBV turns positive — both conditions must fire on a daily close before a long signal is valid. The 60-month backtest produced 263 trades with a 42.6% win rate, a 6.9% return, and a 10.0% maximum drawdown. However, the 24-month window was negative at -7.5% with a 10.5% drawdown, and no parameter variant survived the final holdout — the recommendation is explicitly no-optimization. Treat the current ruleset as the fixed configuration to monitor, not something to tune.

The rotation case has real fundamental teeth

The idea's core claim — that old-economy and consumer-facing companies are carrying the market while AI chips struggle — finds genuine support in the underlying fundamentals. The CNBC coverage of the Dow rising over 400 points to a record while the Nasdaq fell, alongside the Yahoo Finance report on memory-chip supply glut fears hitting SanDisk (-11%), Seagate (-7%), and Micron (-4%), provides a real-time snapshot of this divergence. The Yahoo Finance piece on Tesla's Q2 deliveries beating estimates at 480,126 vehicles validates the demand narrative at the center of the thesis. Eli Lilly's fundamentals are the strongest pillar of the bull case. The company posted 44.7% year-over-year revenue growth, an 83.0% gross margin that places it in the 79th percentile of its Health Care peer group, and a return on equity of 77.8% — in the 91st percentile among 966 peers. That is not just a…

Scores

• Conviction score breakdown: 44
• Thesis support: 58
• Trade readiness: 30
• Risk quality: 45
• Backtest evidence: 35
• Fundamentals trend: 50

Watch items

• TSLA — ADX (14)
• TSLA — Price vs 50-day SMA
• TSLA — OBV
• TSLA — RSI (14)
• DIA — Price vs 50-day SMA
• DIA — Price above 3
• DIA — ADX (14) above 25
• DIA — Price above SMA (50)
• LLY — Price above 3
• LLY — ADX (14) above 25